HighTower Advisors LLC Takes Position in Amneal Pharmaceuticals, Inc. $AMRX

HighTower Advisors LLC purchased a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 89,007 shares of the company’s stock, valued at approximately $1,121,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Abacus Wealth Partners LLC bought a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at $288,000. Convergence Investment Partners LLC lifted its holdings in shares of Amneal Pharmaceuticals by 51.1% during the fourth quarter. Convergence Investment Partners LLC now owns 146,430 shares of the company’s stock valued at $1,845,000 after purchasing an additional 49,513 shares in the last quarter. Swiss Life Asset Management Ltd bought a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at $254,000. Truist Financial Corp lifted its holdings in shares of Amneal Pharmaceuticals by 87.4% during the fourth quarter. Truist Financial Corp now owns 25,608 shares of the company’s stock valued at $323,000 after purchasing an additional 11,944 shares in the last quarter. Finally, Strs Ohio bought a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at $52,000. 31.82% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Stock Performance

AMRX stock opened at $13.52 on Friday. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $7.07 and a fifty-two week high of $15.42. The business’s 50-day moving average is $12.70 and its two-hundred day moving average is $12.96. The company has a market cap of $4.31 billion, a price-to-earnings ratio of 35.58 and a beta of 1.30.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The company had revenue of $722.52 million for the quarter. Equities analysts predict that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Truist Financial upped their price target on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Barclays upped their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Weiss Ratings cut Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, May 26th. UBS Group began coverage on Amneal Pharmaceuticals in a report on Friday, April 17th. They issued a “buy” rating and a $19.00 target price on the stock. Finally, Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Amneal Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $15.17.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the transaction, the director owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.